For research use only. Not for therapeutic Use.
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration and can be used for the research of spinal cord injury[1].
| Catalog Number | I042043 |
| Purity | ≥95% |
| Reference | [1]. Saori Obayashi. Phase 2 Trial of MT-3921 initiated for treatment of spinal cord injury. |
